Wednesday, June 10, 2026

Patent directory · USPTO A61K / A61P

Patents matching “REGENERON PHARMACEUTICALS, INC.”

837 pharma patents match "REGENERON PHARMACEUTICALS, INC." in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 837
Index total 30,257
Page 14 / 35

Quick answer

This filtered view shows 837 pharmaceutical patents matching "REGENERON PHARMACEUTICALS, INC." in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

837 results for “REGENERON PHARMACEUTICALS, INC.” · 30,257 patents in full index Clear search

  1. US 11414494

    Anti-GITR antibodies and uses thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Aug 16, 2022 · Expires Aug 11, 2042

    granted
  2. US 11407813

    Anti-VEGF protein compositions and methods for producing the same

    REGENERON PHARMACEUTICALS, INC. · Granted Aug 9, 2022 · Expires Aug 4, 2042

    granted
  3. US 11407822

    Treatment of fibrodysplasia ossificans progressiva

    REGENERON PHARMACEUTICALS, INC. · Granted Aug 9, 2022 · Expires Aug 4, 2042

    granted
  4. US 11396544

    Bispecific anti-CD28 × anti-CD22 antibodies and uses thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Jul 26, 2022 · Expires Jul 21, 2042

    granted
  5. US 11384153

    Bispecific anti-BCMA x anti-CD3 antibodies and uses thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Jul 12, 2022 · Expires Jul 7, 2042

    granted
  6. US 11377502

    Anti-MSR1 antibodies and methods of use thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Jul 5, 2022 · Expires Jun 30, 2042

    granted
  7. US 11370843

    High affinity antibodies to human IL-6 receptor

    REGENERON PHARMACEUTICALS, INC. · Granted Jun 28, 2022 · Expires Jun 23, 2042

    granted
  8. US 11369896

    Methods for quantitating individual antibodies from a mixture

    REGENERON PHARMACEUTICALS, INC. · Granted Jun 28, 2022 · Expires Jun 23, 2042

    granted
  9. US 11365265

    Anti-C5 antibody combinations and uses thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Jun 21, 2022 · Expires Jun 16, 2042

    granted
  10. US 11359246

    Treatment of obesity with G-protein coupled receptor 75 (GPR75) inhibitors

    REGENERON PHARMACEUTICALS, INC. · Granted Jun 14, 2022 · Expires Jun 9, 2042

    granted
  11. US 11352446

    Methods of making multispecific antigen-binding molecules

    REGENERON PHARMACEUTICALS, INC. · Granted Jun 7, 2022 · Expires Jun 2, 2042

    granted
  12. US 11351256

    Room temperature stable lyophilized protein

    REGENERON PHARMACEUTICALS, INC. · Granted Jun 7, 2022 · Expires Jun 2, 2042

    granted
  13. US 11352417

    Method of treating an allergy with allergen-specific monoclonal antibodies

    REGENERON PHARMACEUTICALS, INC. · Granted Jun 7, 2022 · Expires Jun 2, 2042

    granted
  14. US 11345715

    Biologically active molecules, conjugates thereof, and therapeutic uses

    REGENERON PHARMACEUTICALS, INC. · Granted May 31, 2022 · Expires May 26, 2042

    granted
  15. US 11331332

    Treatment of increased lipid levels with sterol regulatory element binding protein cleavage-activating protein (SCAP) inhibitors

    REGENERON PHARMACEUTICALS, INC. · Granted May 17, 2022 · Expires May 12, 2042

    granted
  16. US 11319375

    Methods and compositions for treating subjects having rheumatoid arthritis

    REGENERON PHARMACEUTICALS, INC. · Granted May 3, 2022 · Expires Apr 28, 2042

    granted
  17. US 11306148

    Anti-NPR1 antibodies and uses thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Apr 19, 2022 · Expires Apr 14, 2042

    granted
  18. US 11306155

    Methods for treating patients with heterozygous familial hypercholesterolemia (heFH) with an anti-PCSK9 antibody

    REGENERON PHARMACEUTICALS, INC. · Granted Apr 19, 2022 · Expires Apr 14, 2042

    granted
  19. US 11306135

    Anti-VEGF protein compositions and methods for producing the same

    REGENERON PHARMACEUTICALS, INC. · Granted Apr 19, 2022 · Expires Apr 14, 2042

    granted
  20. US 11299532

    Anti-VEGF protein compositions and methods for producing the same

    REGENERON PHARMACEUTICALS, INC. · Granted Apr 12, 2022 · Expires Apr 7, 2042

    granted
  21. US 11292847

    Methods for treating atopic dermatitis by administering an IL-4R inhibitor

    REGENERON PHARMACEUTICALS, INC. · Granted Apr 5, 2022 · Expires Mar 31, 2042

    granted
  22. US 11292842

    Anti-PD-1 antibodies for treatment of lung cancer

    REGENERON PHARMACEUTICALS, INC. · Granted Apr 5, 2022 · Expires Mar 31, 2042

    granted
  23. US 11291636

    Polymer protein microparticles

    REGENERON PHARMACEUTICALS, INC. · Granted Apr 5, 2022 · Expires Mar 31, 2042

    granted
  24. US 11286290

    Anti-VEGF protein compositions and methods for producing the same

    REGENERON PHARMACEUTICALS, INC. · Granted Mar 29, 2022 · Expires Mar 24, 2042

    granted